iStock-694432294
print header

Immunization

Meningococcal Conjugate ACYW

The meningococcal conjugate ACYW vaccine protects against illness caused by four types (A, C, Y, and W-135) of meningococcal bacteria (Neisseria meningitidis).

• Routinely given to grade 7 students as part of the school immunization program. This provides a booster dose for group C which they should have received at 1 year of age, as well as protection against three additional strains of this bacteria. This is free for all students born in or after 1997.
• This vaccine is only available publicly funded (free) for those in the following high risk groups :

• Anyone who does not have a spleen, or whose spleen is not working well.
• Anyone with congenital complement, properdin, factor D deficiency or primary antibody deficiencies.
• Anyone who has or will have a cochlear implant.
• Anyone who has HIV.
• Anyone with acquired complement deficiencies.
• Close contacts of those infected.

• This vaccine may be recommended for others based on risk factors, however they would have to purchase this vaccine.

• 80-85 % of people were protected, 3-4 years following vaccination as a teenager.
• Effectiveness does wane over time and booster doses are recommended to those who are at a higher risk.

• At this time there are no other ways to prevent this disease. Hand washing and covering the mouth and nose while coughing/sneezing can help reduce the spread of disease.
• Meningococcal bacteria is also spread by sharing items that come in contact with the nose and throat (i.e. lipstick, water bottles, straws, toothbrushes), so not sharing these items decreases the risk of spreading this bacteria.

• The risk of a serious reaction or side effect from this vaccine is much less than the risk of meningococcal disease.
• If you experience any side effect worse than what is listed below, please seek medical advice and notify the health unit. 

Common

• Pain in the muscle
• Swelling
• Redness
• Fatigue
• Headache
• Fever

Rare

• Anaphylaxis

* Guillain-Barre Syndrome (GBS) was initially raised as a concern due to case reports to the Vaccine Adverse Event Reporting System (VAERS) in the United States, following Menactra® injection. Two large studies were since conducted, and 0 cases of GBS were seen during the 6 weeks following over 2.2 million doses given to 11-21 year olds.

 

• Anyone with an allergy to any of the vaccine components or who has had an allergic or anaphylactic reaction to meningococcal vaccine.

Menactra®

Menveo™

Nimenrix

Also found in…

Diphtheria toxoid

Diphtheria toxoid

 

Other vaccines

Sodium Chloride

Sodium Chloride

Sodium Chloride

Table Salt

Sodium Phosphate dibasic, monobasic

 

 

Laxatives, food additive-emulsifier, leavening agent for baked goods

 

Disodium hydrogen phosphate bihydrate

 

Laxatives, food additive-emulsifier, leavening agent for baked goods

 

Potassium dihydrogen phosphate

 

Laxatives, food additive-emulsifier, leavening agent for baked goods

 

Sodium dihydrogen phosphate monohydrate

 

Laxatives, food additive-emulsifier, leavening agent for baked goods

 

Sucrose

Sucrose

Table sugar

 

 

Trometamol

Medication- for Metabolic Acidosis

Click the share button to:

• Tell us about the immunizations your child received
• Get your child’s immunization record

  Immunization Online Logo

Did you find what you were looking for today?
What did you like about this page?
How can we improve this page?
Page
Feedback

If you have any questions or concerns that require a response, please contact Health Connection directly.

Thanks for your feedback.
Failed to submit comment. Please try submitting again or contact us at the Health Unit.
Comment already submitted ...